We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (diazoxide choline) ...

The company is currently developing Diazoxide Choline Extended-Release (DCCR), a tablet that treats Prader-Willi Syndrome (PWS), a genetic disorder. The drug has already completed its phase 3 trials ...

On Tuesday, the biopharmaceutical company said the U.S. Food and Drug Administration found no apparent need for an advisory committee meeting at this time for Soleno's application for DCCR, or ...

The company is currently developing Diazoxide Choline Extended-Release (DCCR), a tablet that treats Prader-Willi Syndrome (PWS), a genetic disorder. The drug has already completed its phase 3 ...

Soleno Therapeutics (NASDAQ:SLNO) is a biotech company that focuses on rare diseases, particularly Prader-Willi Syndrome (PWS) hyperphagia. PWS is a genetic condition that creates insatiable ...

Mum-of-five Katie Price says son Harvey, 22, needs a little support with his walking and after cane training, his very own ...

For these reasons, and others, Australian sociologist Judy Singer, who coined the phrase neurodiversity, wanted the narrative ...

This is a new drug application (NDA) for the company's diazoxide choline (DCCR) tablets aimed at the treatment of genetic disorder Prader-Willi Syndrome. Soleno isn't entirely in the clear to skip ...

Soleno Therapeutics (SLNO) shares rose 15% in premarket trade after FDA announced no advisory committee meeting needed for ...